Aktis Oncology (AKTS), a radiopharmaceutical drug developer backed by pharma giants such as Eli Lilly (LLY), has filed its preliminary regulatory filings with the Securities and Exchange Commission ...
Hosted on MSN
Lilly-backed radiophama startup Atkis seeks U.S. IPO
Aktis Oncology (AKTS), a radiopharmaceutical drug developer backed by pharma giants such as Eli Lilly (LLY), has filed its preliminary regulatory filings with the Securities and Exchange Commission ...
89 x 59 cm. (35 x 23.2 in.) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results